Blueprint Medicines Corporation (BPMC) stock surged 5.01% during intraday trading on Friday, continuing its upward momentum following the company's recent first-quarter earnings report and raised guidance. Despite missing earnings and revenue estimates, investors appear to be focusing on the company's strong product sales and optimistic outlook.
The biotech firm reported a wider-than-expected Q1 loss of 74 cents per share, compared to the anticipated loss of 42 cents. Revenues of $149.4 million, generated entirely from Ayvakit sales, also fell short of expectations. However, Ayvakit sales showed impressive growth, jumping 61% year-over-year to $149.4 million, driven by new patient starts and high compliance rates.
Blueprint Medicines raised its 2025 guidance for global Ayvakit net product revenues to $700-$720 million, up from the previous range of $680-$710 million. This increase, coupled with the company's long-term sales target of $2 billion for Ayvakit by 2030, seems to have bolstered investor confidence. Additionally, positive updates on the company's pipeline, including progress with BLU-808 for various indications, may be contributing to the stock's upward movement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.